FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2189346095> ?p ?o ?g. }

• W2189346095 endingPage "738" @default.
• W2189346095 startingPage "737" @default.
• W2189346095 abstract "In the early 1990's several groups were searching for the molecular basis of the signal transduction triggered by the engagement of plasma membrane receptors. The laboratories of Darnell, Kerr and Stark were first to identify proteins, which acted as intermediaries in interferon (IFN) signaling, known as the signal transducer and activator of transcription (STAT). At the same time, the work of Pellegrini's, Ihle's and Carter-Su's groups demonstrated that non-receptor tyrosine kinases, previously described by John Krolewski and Andrew Wilks, called Janus Kinases (JAK), played a role in cytokine receptor signaling. We have since learned that multiple negative regulators, mainly tyrosine phosphatase (SHP), Protein Inhibitors Against Stats (PIAS), and Suppressor Of Cytokine Signaling (SOCS) proteins, modulate and eventually extinguish JAK-STAT signaling [1].In invertebrates a single JAK-STAT module controls anti-viral and anti-bacterial responses, leukocyte-like hemocyte generation, cell fate determination, brain development, cardiogenesis, as well as intestinal stem cells. The increase of JAK-STAT pathway components has coincided with the emergence of adaptive immunity and the expansion and diversification of cytokine receptors. As ligands bind to cognate receptors, they trigger the recruitment and activation of JAKs. Activated JAKs can then phosphorylate the receptor favoring the STAT docking and ultimately their activation via tyrosine phosphorylation. Phospho-STAT dimers accumulate in the cell nucleus, bind to enhancer elements and regulate gene expression. In parallel, JAKs may fire other downstream signaling cascades (MAP kinase and PI-3-kinase/AKT pathways), or within the nucleus by phosphorylating DNA regulatory proteins (histone H3 and methyltransferase) modulate gene expression and the epigenetic program of cells [2].There is comprehensive evidence that abnormal JAK/STAT signals can lead to immunodeficiencies, a spectrum of cytokine mediated inflammatory diseases and cancer. Hyperactivation of STAT signaling is common in hematopoietic disorders through several different mechanisms [2-3]. JAK2 amplification, loss of SOCS1 and phosphatases, as well as somatic mutations of STAT3 and STAT6 are seen in mediastinal B-cell, grey zone, Hodgkin and Diffuse Large B-cell lymphomas. Activating mutations of JAK1-3 and STAT3-5 were also found in a subset of NK/T-cell, non-hepatosplenic gamma-delta T-cell lymphoma and T-cell prolymphocytic leukemia. Moreover, the constitutive activation of STAT is also observed in cells carrying tyrosine kinase fusions. This is epitomized in Anaplastic Large Cell Lymphomas (ALCL) carrying Anaplastic Lymphoma Kinase (ALK) fusions. In these settings, STAT3 inhibition inevitably leads to cell cycle arrest followed by apoptosis [4-5].Searching for genomic defects responsible for the transformation and the maintenance of the neoplastic phenotype of ALK-ALCL, our groups have used massive genomic sequencing. These studies demonstrated the presence of recurrent activating mutations of JAK1 and/or STAT3 and novel tyrosine kinase fusions. JAK1 and STAT3 mutants result in a hyperactivated STAT3, which sustains cell transformation, and whose pharmacological ablation produces tumor cell growth inhibition. Interestingly, we found that ~30% of systemic pSTAT3 positive ALK-ALCL carry both JAK1 and STAT3 mutations that work synergistically [5]. Further analyses showed that in single JAK1 or STAT3 mutants, non-sense mutations and genomic loss of negative regulators (PTPRC/D) can be detected, suggesting that convergent mutations on the same pathway might be selected. However, the association of two mutations that are convergent in genes coding for two interplaying proteins is unexpected. The probability of mutations at a particular site is small, when randomly distributed along the genome, and conditionally independent of previous mutations. Thus the probability of double mutations is theoretically the square of the probability of a single mutation. The strong association between JAK/STAT mutations argues for a set of complementary and overlapping explanations: 1) a significant clonal expansion of single mutant fostering the emergency of susceptible tumor cells, 2) strong selection in double mutants, 3) differential off-pathway events of different mutations, or 4) preferential mutational hotspots. These hypotheses offer fascinating possibilities, including the identification of early clones that mark disease progression. Currently, our groups are trying to create a model for clonal evolution in ALCL.Figure 1Convergent effect of JAK1 and STAT3 mutations in ALK - Anaplastic Large Cell Lymphoma (ALCL)Although JAK1/STAT3 mutants are oncogenic, they require lymphokine engagement (i.e. IL-6, IL-23) and JAK activation, whose inhibition (Ruxolitinib, HSP90) leads to STAT3 dephosphorylation, cell growth inhibition and lymphoma control in a Patient Derived Tumor Xenografted (PDTX) model. In addition, STAT3 hyperactivation forces the preferential differentiation of T-cells and the secretion of selective lymphokines (IL-17, IL-22). Therefore, the inflammatory phenotype associated with ALCL hijacks host elements and favors protumorigenic phenotypes (i.e. neutrophils, macrophages) and/or the emergency recruitment of immunosuppressive T-cells.These data validate JAK and STAT as therapeutic targets. Inhibitors of JAKs were recently introduced and it is anticipated that these new therapies, either alone or in combination, might be beneficial [7-8]. We predict these compounds, which generally have reasonable toxicities, might limit the adverse side effects of conventional chemotherapy and/or allow lower doses, possibly increasing responses and sustained remissions. There are several compounds that are currently being tested or have been approved for different disorders that could be evaluated in molecularly stratified cancer patients. Thus, the genotyping of future lymphoma patients will become invaluable to the treatment of disease. Our groups are now pursuing this strategy, hoping to identify naive and/or refractory patients, who are eligible for novel targeted therapies. These studies are critical to determine the oncogenic role of the JAK/STAT pathways along different clinical stages. This, in combination with the execution of co-clinical trials and Patient Derived Tumor Xenograft (PDTX) models, should open new personalized/precision therapies that will undoubtedly improve clinical success and patient outcomes." @default.
• W2189346095 created "2016-06-24" @default.
• W2189346095 creator A5006640724 @default.
• W2189346095 creator A5056128255 @default.
• W2189346095 date "2015-08-11" @default.
• W2189346095 modified "2023-10-16" @default.
• W2189346095 title "JAK-STAT in lymphoproliferative disorders" @default.
• W2189346095 cites W1968235930 @default.
• W2189346095 cites W1973454407 @default.
• W2189346095 cites W2007739717 @default.
• W2189346095 cites W2028544780 @default.
• W2189346095 cites W2147915026 @default.
• W2189346095 cites W2158312458 @default.
• W2189346095 cites W259732519 @default.
• W2189346095 cites W644234115 @default.
• W2189346095 doi "https://doi.org/10.18632/oncoscience.189" @default.
• W2189346095 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4606001" @default.
• W2189346095 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26501073" @default.
• W2189346095 hasPublicationYear "2015" @default.
• W2189346095 type Work @default.
• W2189346095 sameAs 2189346095 @default.
• W2189346095 citedByCount "1" @default.
• W2189346095 countsByYear W21893460952017 @default.
• W2189346095 crossrefType "journal-article" @default.
• W2189346095 hasAuthorship W2189346095A5006640724 @default.
• W2189346095 hasAuthorship W2189346095A5056128255 @default.
• W2189346095 hasBestOaLocation W21893460951 @default.
• W2189346095 hasConcept C101544691 @default.
• W2189346095 hasConcept C108636557 @default.
• W2189346095 hasConcept C112392421 @default.
• W2189346095 hasConcept C11960822 @default.
• W2189346095 hasConcept C126042315 @default.
• W2189346095 hasConcept C154390347 @default.
• W2189346095 hasConcept C157333092 @default.
• W2189346095 hasConcept C171958077 @default.
• W2189346095 hasConcept C2775855021 @default.
• W2189346095 hasConcept C2777553839 @default.
• W2189346095 hasConcept C2778277574 @default.
• W2189346095 hasConcept C2778923194 @default.
• W2189346095 hasConcept C502942594 @default.
• W2189346095 hasConcept C62478195 @default.
• W2189346095 hasConcept C86803240 @default.
• W2189346095 hasConcept C95444343 @default.
• W2189346095 hasConceptScore W2189346095C101544691 @default.
• W2189346095 hasConceptScore W2189346095C108636557 @default.
• W2189346095 hasConceptScore W2189346095C112392421 @default.
• W2189346095 hasConceptScore W2189346095C11960822 @default.
• W2189346095 hasConceptScore W2189346095C126042315 @default.
• W2189346095 hasConceptScore W2189346095C154390347 @default.
• W2189346095 hasConceptScore W2189346095C157333092 @default.
• W2189346095 hasConceptScore W2189346095C171958077 @default.
• W2189346095 hasConceptScore W2189346095C2775855021 @default.
• W2189346095 hasConceptScore W2189346095C2777553839 @default.
• W2189346095 hasConceptScore W2189346095C2778277574 @default.
• W2189346095 hasConceptScore W2189346095C2778923194 @default.
• W2189346095 hasConceptScore W2189346095C502942594 @default.
• W2189346095 hasConceptScore W2189346095C62478195 @default.
• W2189346095 hasConceptScore W2189346095C86803240 @default.
• W2189346095 hasConceptScore W2189346095C95444343 @default.
• W2189346095 hasIssue "9" @default.
• W2189346095 hasLocation W21893460951 @default.
• W2189346095 hasLocation W21893460952 @default.
• W2189346095 hasLocation W21893460953 @default.
• W2189346095 hasLocation W21893460954 @default.
• W2189346095 hasOpenAccess W2189346095 @default.
• W2189346095 hasPrimaryLocation W21893460951 @default.
• W2189346095 hasRelatedWork W1981896461 @default.
• W2189346095 hasRelatedWork W1981962627 @default.
• W2189346095 hasRelatedWork W2032735246 @default.
• W2189346095 hasRelatedWork W2055061133 @default.
• W2189346095 hasRelatedWork W2074344355 @default.
• W2189346095 hasRelatedWork W2075216710 @default.
• W2189346095 hasRelatedWork W2110369495 @default.
• W2189346095 hasRelatedWork W2111237323 @default.
• W2189346095 hasRelatedWork W2129479739 @default.
• W2189346095 hasRelatedWork W2160289258 @default.
• W2189346095 hasRelatedWork W2399467729 @default.
• W2189346095 hasRelatedWork W2468750025 @default.
• W2189346095 hasRelatedWork W2568503677 @default.
• W2189346095 hasRelatedWork W2751598965 @default.
• W2189346095 hasRelatedWork W2765770316 @default.
• W2189346095 hasRelatedWork W2992092023 @default.
• W2189346095 hasRelatedWork W2998258401 @default.
• W2189346095 hasRelatedWork W3205151267 @default.
• W2189346095 hasRelatedWork W605873440 @default.
• W2189346095 hasRelatedWork W2548342657 @default.
• W2189346095 hasVolume "2" @default.
• W2189346095 isParatext "false" @default.
• W2189346095 isRetracted "false" @default.
• W2189346095 magId "2189346095" @default.
• W2189346095 workType "article" @default.